 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Changes in the Use of Postmenopausal Hormone Replacement Therapy after the Publication of Study Results
3 February 2004 | Volume 140 Issue 3 | Page I-50
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results." It is in the 3 February 2004 issue of Annals of Internal Medicine (volume 140, pages 184–188). The authors are J.S. Haas, C.P. Kaplan, E.P. Gerstenberger, and K. Kerlikowske.
What is the problem and what is known about it so far?
Menopause is the time when a woman's ovaries permanently decrease production of the hormones estrogen and progesterone. This reduction in hormone levels leads to the end of menstruation. In the years around menopause, the changes in hormone levels result in symptoms, including hot flashes, night sweats, mood swings, and vaginal dryness. The lower hormone levels also put women at risk for osteoporosis and heart disease. Postmenopausal hormone replacement therapy (HRT) refers to regimens of the female hormone estrogen with or without progesterone. Hormone replacement therapy reduces the uncomfortable symptoms of menopause. It also influences the development (favorably and unfavorably) of conditions including osteoporosis (thinning of the bones that can lead to fractures), heart disease, stroke, blood clots, dementia, and cancer (colon, breast, and uterine). Before the publication of the results of 2 large studies, the Heart and Estrogen/progestin Study (HERS) in 1998 and the Women's Health Initiative (WHI) in 2002, research suggested that the benefits of HRT outweighed the risks. However, HERS and the WHI, which were of higher quality than previous studies, showed that women taking HRT actually had a higher risk for heart disease and stroke than women not taking HRT. The results of the WHI received substantial media attention.
Why did the researchers do this particular study?
To describe changes in HRT use after publication of the 2 largest and best-quality studies on HRT.
Who was studied?
Postmenopausal women who underwent mammography in San Francisco, California, between January 1997 and 19 May 2003.
How was the study done?
At the time of each mammogram, women answered questions about their health and HRT use. The researchers looked at the proportion of women who were taking HRT each quarter year over the study period. They were most interested in patterns of use after publication of HERS in August 1998 and the WHI in July 2002.
What did the researchers find?
The proportion of women who were taking HRT was increasing slowly in the period before HERS publication but decreased slightly after HERS publication in 1998 and decreased dramatically after WHI publication in 2002. The decreases in use were not associated with age, hysterectomy status, or ethnic background.
What were the limitations of the study?
The results might not apply to women in other geographic areas or women who do not undergo mammography. In addition, the study ended too soon to show whether the decreases in HRT use after WHI publication continued, stabilized, or started to rise.
What are the implications of the study?
The changes in HRT use following WHI publication are more dramatic than those usually seen with the publication of new studies. The large amount of media attention and the fact that the WHI was the second large study to show that the risks of HRT may outweigh the benefits may have contributed to the changes.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  L. Fejerman, E. M. John, S. Huntsman, K. Beckman, S. Choudhry, E. Perez-Stable, E. G. Burchard, and E. Ziv Genetic Ancestry and Risk of Breast Cancer among U.S. Latinas Cancer Res., December 1, 2008; 68(23): 9723 - 9728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Sprague, A. Trentham-Dietz, K. M. Egan, L. Titus-Ernstoff, J. M. Hampton, and P. A. Newcomb Proportion of Invasive Breast Cancer Attributable to Risk Factors Modifiable after Menopause Am. J. Epidemiol., August 15, 2008; 168(4): 404 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Li, S. Chapman, K. Agho, and C. J. Eastman Can even minimal news coverage influence consumer health-related behaviour? A case study of iodized salt sales, Australia Health Educ. Res., June 1, 2008; 23(3): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Krieger Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections Int. J. Epidemiol., June 1, 2008; 37(3): 627 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kim, E. J. Perez-Stable, S. Wong, S. Gregorich, G. F. Sawaya, J. M. E. Walsh, and C. P. Kaplan Association Between Cancer Risk Perception and Screening Behavior Among Diverse Women Arch Intern Med, April 14, 2008; 168(7): 728 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schulkin Hormone Therapy, Dilemmas, Medical Decisions. J. Law Med. Ethics, March 1, 2008; 36(1): 73 - 88. [PDF]
|
|
|
|
 |
|
 K. Kerlikowske, D. L. Miglioretti, D. S. M. Buist, R. Walker, and P. A. Carney Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population J Natl Cancer Inst, September 5, 2007; 99(17): 1335 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Patel and R. M. Derkits Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration Journal of Pharmacy Practice, August 1, 2007; 20(4): 341 - 346. [Abstract] [PDF]
|
|
|
|
|
|
A. G. Glass, J. V. Lacey Jr, J. D. Carreon, and R. N. Hoover Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status J Natl Cancer Inst, August 1, 2007; 99(15): 1152 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Clegg Smith, J. Cho, A. Gielen, and J. S Vernick Newspaper coverage of residential fires: an opportunity for prevention communication Inj. Prev., April 1, 2007; 13(2): 110 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Canonico, E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Levesque, N. Trillot, M.-T. Barrellier, D. Wahl, J. Emmerich, et al. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study Circulation, February 20, 2007; 115(7): 840 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Everett, T. Kurth, J. E. Buring, and P. M. Ridker The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2235 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Smigal, A. Jemal, E. Ward, V. Cokkinides, R. Smith, H. L. Howe, and M. Thun Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin, May 1, 2006; 56(3): 168 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Giordano, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, J. Freeman, and J. S. Goodwin Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst, March 15, 2006; 98(6): 382 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Florida Behavioral Health Research Consortium, M. A. Burg, K. Fraser, S. Gui, K. Grant, S. G. Kosch, B. Nierenberg, O. Oyama, H. Pomm, K. Sibille, et al. Treatment of Menopausal Symptoms in Family Medicine Settings following the Women's Health Initiative Findings J Am Board Fam Med, March 1, 2006; 19(2): 122 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wei, D. L. Miglioretti, M. T. Connelly, S. E. Andrade, K. M. Newton, C. L. Hartsfield, K. A. Chan, and D. S. M. Buist Changes in Women's Use of Hormones After the Women's Health Initiative Estrogen and Progestin Trial by Race, Education, and Income J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Mayer, C. A. Dyer, R. L. Eastgard, P. B. Hoyer, and C. L. Banka Atherosclerotic Lesion Development in a Novel Ovary-Intact Mouse Model of Perimenopause Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1910 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J Coombs, R. Taylor, N. Wilcken, and J. Boyages Hormone replacement therapy and breast cancer: estimate of risk BMJ, August 6, 2005; 331(7512): 347 - 349. [Full Text] [PDF]
|
|
|
|
 |
|
 Effect of Media Reports on Clinical Practice: The Example of Hormone Therapy Journal Watch (General), February 20, 2004; 2004(220): 4 - 4. [Full Text]
|
|
|
|
 |
|
 L. M. Schwartz and S. Woloshin The Media Matter: A Call for Straightforward Medical Reporting Ann Intern Med, February 3, 2004; 140(3): 226 - 228. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
